$CANB
Can B Corp Stock $canb

$canb Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014686 Filed on April 15, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$272.3K	$376.9K	$2.156M
YoY Change	-35.26%	-43.42%	-67.76%
Cost Of Revenue	$665.5K	-$897.6K	$1.797M
YoY Change	-28.78%	-209.35%	-55.86%
Gross Profit	-$393.2K	$1.274M	$358.7K
YoY Change	-23.48%	-923.58%	-86.28%
Gross Profit Margin	-144.4%	338.16%	16.64%
Selling, General & Admin	$1.174M	$4.749M	$4.749M
YoY Change	-10.24%	-62.36%	412.45%
% of Gross Profit		372.6%	1323.93%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$29.17K	$350.0K	$1.400M
YoY Change	-91.64%	0.15%	-0.58%
% of Gross Profit		27.46%	390.3%
Operating Expenses	$1.174M	$1.926M	$7.845M
YoY Change	-10.24%	-20.89%	-53.25%
Operating Profit	-$1.567M	-$651.7K	-$7.486M
YoY Change	-13.98%	-74.83%	-47.16%
Interest Expense	-$463.4K	-$1.175M	-$2.511M
YoY Change	-211.28%	283.03%	-378.32%
% of Operating Profit
Other Income/Expense, Net	-$461.6K	$20.69K	$269.4K
YoY Change	124.73%	-999.57%	-135.67%
Pretax Income	-$2.029M	-$1.806M	-$9.728M
YoY Change	0.08%	-37.69%	-34.81%
Income Tax		$0.00	$9.600K
% Of Pretax Income
Net Earnings	-$2.029M	-$1.806M	-$9.737M
YoY Change	0.08%	-37.71%	-34.75%
Net Earnings / Revenue	-745.03%	-479.2%	-451.7%
Basic Earnings Per Share	-$0.04		-$0.77
Diluted Earnings Per Share	-$0.04	-$0.06	-$0.77
COMMON SHARES
Basic Shares Outstanding	49.34M shares	26.25M shares	12.59M shares
Diluted Shares Outstanding	54.63M shares		12.59M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$0.00	$34.01K	$34.01K
YoY Change	-100.0%	-53.53%	-53.53%
Cash & Equivalents		$34.01K	$34.01K
Short-Term Investments
Other Short-Term Assets	$10.06K	$4.140K	$4.140K
YoY Change	-65.48%	-80.3%	-80.3%
Inventory	$563.4K	$1.620M	$1.620M
Prepaid Expenses
Receivables	$3.405M	$3.723M	$3.723M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.978M	$5.381M	$5.381M
YoY Change	-52.78%	-38.18%	-38.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$619.9K	$4.401M	$4.401M
YoY Change	-87.09%	-18.98%	-33.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.63K	$248.6K	$248.6K
YoY Change	26.54%	1791.77%	38.91%
Total Long-Term Assets	$941.6K	$4.745M	$4.745M
YoY Change	-84.7%	-30.78%	-30.78%
TOTAL ASSETS
Total Short-Term Assets	$3.978M	$5.381M	$5.381M
Total Long-Term Assets	$941.6K	$4.745M	$4.745M
Total Assets	$4.920M	$10.13M	$10.13M
YoY Change	-66.26%	-34.92%	-34.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.614M	$1.945M	$1.945M
YoY Change	-28.94%	-38.06%	-38.06%
Accrued Expenses	$65.77K	$254.4K	$254.4K
YoY Change	-83.78%	40.01%	-69.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.983M	$8.569M	$8.569M
YoY Change	-7.42%	7.78%	7.78%
Total Short-Term Liabilities	$11.11M	$11.13M	$11.13M
YoY Change	-19.02%	-10.43%	-10.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.11M	$11.13M	$11.13M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$11.11M	$11.13M	$11.13M
YoY Change	-20.78%	-13.48%	-13.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.7M	-$102.4M
YoY Change	14.74%	10.51%
Common Stock	$85.15M	$83.26M
YoY Change	6.04%	4.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$572.7K	$572.7K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$6.191M	-$1.002M	-$1.002M
YoY Change
Total Liabilities & Shareholders Equity	$4.920M	$10.13M	$10.13M
YoY Change	-66.26%	-34.92%	-34.92%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.029M	-$1.806M	-$9.737M
YoY Change	0.08%	-37.71%	-34.75%
Depreciation, Depletion And Amortization	$29.17K	$350.0K	$1.400M
YoY Change	-91.64%	0.15%	-0.58%
Cash From Operating Activities	-$131.1K	$151.4K	-$1.305M
YoY Change	-61.81%	-128.76%	-66.95%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$15.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$3.870K	$370.00	-$69.63K
YoY Change
Cash From Investing Activities	-$3.870K	$370.00	-$84.63K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	108.2K	-149.1K	1.350M
YoY Change	-59.98%	-126.38%	-62.2%
NET CHANGE
Cash From Operating Activities	-131.1K	151.4K	-1.305M
Cash From Investing Activities	-3.870K	370.0	-84.63K
Cash From Financing Activities	108.2K	-149.1K	1.350M
Net Change In Cash	-26.73K	2.680K	-39.19K
YoY Change	-63.29%	-93.08%	-89.57%
FREE CASH FLOW
Cash From Operating Activities	-$131.1K	$151.4K	-$1.305M
Capital Expenditures		$0.00	$15.00K
Free Cash Flow		$151.4K	-$1.320M
YoY Change		-128.76%	-66.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001509957
CY2023	dei	Entity Registrant Name EntityRegistrantName	Can B Corp
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	CANB	Common Stock In Lieu Of Cash Payroll CommonStockInLieuOfCashPayroll		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2023	CANB	Loss On Sale Of Property Plant Equipment LossOnSaleOfPropertyPlantEquipment		usd
CY2022	CANB	Cancellation Of Debt CancellationOfDebt		usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	CANB	Payments For Deposit PaymentsForDeposit		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	CANB	Proceeds From Issuance Of Series D Preferred Stock ProceedsFromIssuanceOfSeriesDPreferredStock		usd
CY2022	CANB	Proceeds From Issuance Of Series D Preferred Stock ProceedsFromIssuanceOfSeriesDPreferredStock		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	CANB	Issuance Of Common Stock In Lieu Of Repayments Of Notes Payable IssuanceOfCommonStockInLieuOfRepaymentsOfNotesPayable		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	CANB	Assets Acquired Through Issuance Of Promissory Note AssetsAcquiredThroughIssuanceOfPromissoryNote		usd
CY2022	CANB	Assets Acquired Through Issuance Of Promissory Note AssetsAcquiredThroughIssuanceOfPromissoryNote		usd
CY2023	CANB	Issuance Of Common Stock Resulting From Exercise Of Warrants IssuanceOfCommonStockResultingFromExerciseOfWarrants		usd
CY2022	CANB	Issuance Of Common Stock Warrants And Commitment Shares In Connection With Convertible Promissory Note IssuanceOfCommonStockWarrantsAndCommitmentSharesInConnectionWithConvertiblePromissoryNote		usd
CY2023	CANB	Issuance Of Warrant Liabilities IssuanceOfWarrantLiabilities		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55753
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3624118
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	960 South Broadway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 120
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Hicksville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11801
CY2023	dei	City Area Code CityAreaCode	516
CY2023	dei	Local Phone Number LocalPhoneNumber	595-9544
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1017685	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49344230	shares
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34006	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73194	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2818395	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	985028	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3723344	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6586210	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1619542	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2024053	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4138	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21024	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5381029	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8704481	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	235418	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	165787	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	95144	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	107144	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4106283	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5432357	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	295151	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1136883	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13139	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13139	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	4745135	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	6855310	usd
CY2023Q4	us-gaap	Assets Assets	10126164	usd
CY2022Q4	us-gaap	Assets Assets	15559791	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1945243	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3140408	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	181700	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	8569489	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	7951196	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1766	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	203043	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	254391	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	652172	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11128132	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12423762	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	438104	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	438104	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11128132	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12861866	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4422584	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4422584	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2834755	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2834755	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	83263105	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	79614986	usd
CY2023Q4	CANB	Common Stock Issuable No Par Value CommonStockIssuableNoParValue	0
CY2022Q4	CANB	Common Stock Issuable No Par Value CommonStockIssuableNoParValue	0
CY2023Q4	CANB	Common Stock Issuable Shares CommonStockIssuableShares	36248
CY2022Q4	CANB	Common Stock Issuable Shares CommonStockIssuableShares	0
CY2023Q4	CANB	Common Stock Issuable Value CommonStockIssuableValue	119586	usd
CY2022Q4	CANB	Common Stock Issuable Value CommonStockIssuableValue	119586	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	572678	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	572678	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10396274	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8006822	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102428298	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92690834	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1001968	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2697925	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10126164	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15559791	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2155744	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6685519	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1797047	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4071144	usd
CY2023	us-gaap	Gross Profit GrossProfit	358698	usd
CY2022	us-gaap	Gross Profit GrossProfit	2614375	usd
CY2023	CANB	Compensation Operating Expenses CompensationOperatingExpenses	2923858	usd
CY2022	CANB	Compensation Operating Expenses CompensationOperatingExpenses	7199215	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	1824952	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	5416006	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	3096330	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	4167301	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	7845140	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	16782522	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7486442	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-14168147	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-201277	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-154010	usd
CY2023	us-gaap	Interest Expense InterestExpense	2510811	usd
CY2022	us-gaap	Interest Expense InterestExpense	902130	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	68108	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7115	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2241426	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-755235	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9727868	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14923382	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9596	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	793	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9737464	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14924175	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.18
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12590147	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12590147	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3570087	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3570087	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5619515	usd
CY2022	CANB	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	2	usd
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	500000	usd
CY2022	CANB	Stock Issued During Period Value Issuance Of Common Stock In Lieu Of Note Interest Repayments StockIssuedDuringPeriodValueIssuanceOfCommonStockInLieuOfNoteInterestRepayments	73078	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4489842	usd
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	98666	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1767498	usd
CY2022	CANB	Issuance Of Common Stock Resulting From Exercise Of Warrants IssuanceOfCommonStockResultingFromExerciseOfWarrants	8641	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5064858	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14924175	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2697925	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2697925	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1046194	usd
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	46875	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	937787	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	589216	usd
CY2023	CANB	Stock Issued During Period Value Purchase Of Inventory StockIssuedDuringPeriodValuePurchaseOfInventory	175500	usd
CY2023	CANB	Issuance Of Common Stock In Lieu Of Interest Payment IssuanceOfCommonStockInLieuOfInterestPayment	328932	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	185499	usd
CY2023	CANB	Stock Issued During Period Value In Lieu Note Repayments StockIssuedDuringPeriodValueInLieuNoteRepayments	1275903	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1451665	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9737464	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1001968	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1001968	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9737464	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14924175	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1451665	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5064860	usd
CY2023	CANB	Common Stock In Lieu Of Cash Payroll CommonStockInLieuOfCashPayroll	589216	usd
CY2023	us-gaap	Depreciation Depreciation	1387949	usd
CY2022	us-gaap	Depreciation Depreciation	1408061	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26906	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1417583	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	444920	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1833367	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	751025	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	252462	usd
CY2022	CANB	Loss On Sale Of Property Plant Equipment LossOnSaleOfPropertyPlantEquipment	309000	usd
CY2023	CANB	Cancellation Of Debt CancellationOfDebt	-110000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-201277	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-154010	usd
CY2023	CANB	Stockbased Interest Expense StockbasedInterestExpense	328932	usd
CY2022	CANB	Stockbased Interest Expense StockbasedInterestExpense	73078	usd
CY2023	CANB	Stockbased Consulting Expense StockbasedConsultingExpense	1046194	usd
CY2022	CANB	Stockbased Consulting Expense StockbasedConsultingExpense	4489842	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1029499	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3690558	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-580011	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-529385	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-16887	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	14327	usd
CY2023	CANB	Increase Decrease In Lease Right Of Use Asset IncreaseDecreaseInLeaseRightOfUseAsset	-5847	usd
CY2022	CANB	Increase Decrease In Lease Right Of Use Asset IncreaseDecreaseInLeaseRightOfUseAsset	26764	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-954904	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1988699	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-475828	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1304495	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3947424	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000	usd
CY2023	CANB	Payments For Deposit PaymentsForDeposit	69631	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-84631	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2405000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3449853	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	500000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	939062	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	377500	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	178000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	77706	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	62000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	76970	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1349938	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3571617	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39188	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-375807	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73194	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	449001	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34006	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73194	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1075	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	83147	usd
CY2023	CANB	Issuance Of Common Stock In Lieu Of Repayments Of Notes Payable IssuanceOfCommonStockInLieuOfRepaymentsOfNotesPayable	1275903	usd
CY2023	CANB	Issuance Of Common Stock In Acquisition Of Note Payable Commitment Shares IssuanceOfCommonStockInAcquisitionOfNotePayableCommitmentShares	175500	usd
CY2022	CANB	Issuance Of Common Stock In Acquisition Of Note Payable Commitment Shares IssuanceOfCommonStockInAcquisitionOfNotePayableCommitmentShares	1767498	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	46875	usd
CY2023	CANB	Debt Discount Associated With Convertible Note DebtDiscountAssociatedWithConvertibleNote	273529	usd
CY2022	CANB	Debt Discount Associated With Convertible Note DebtDiscountAssociatedWithConvertibleNote	357049	usd
CY2022	CANB	Issuance Of Common Stock Resulting From Exercise Of Warrants IssuanceOfCommonStockResultingFromExerciseOfWarrants	8641	usd
CY2023	CANB	Issuance Of Common Stock Warrants And Commitment Shares In Connection With Convertible Promissory Note IssuanceOfCommonStockWarrantsAndCommitmentSharesInConnectionWithConvertiblePromissoryNote	937787	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34006	usd
CY2023Q4	CANB	Working Capital WorkingCapital	-5747103	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9737464	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14924175	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a 1-for-15 reverse stock split of the Company’s common stock, or the 2021 Reverse Stock Split. As a result of the 2021 Reverse Stock Split, every 15 shares of the Company’s pre-2021 Reverse Stock Split common stock were combined and reclassified into one share of the Company’s common stock.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_ziJlIl7JAgLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zAodC4DYqemb">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales (or revenues) and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that estimates made as of the date of the financial statements could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include, but are not limited to, revenue recognition, allowance for doubtful accounts, recognition and measurement of income tax assets, valuation of share-based compensation, and the valuation of net assets acquired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	14500	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zugf4mCewbI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zWJ8qlpnRxp5">Concentration of business and credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents and accounts receivable. Cash held by the Company, in financial institutions, may exceed the federally insured limit of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zY0wh0lGV70a" title="Cash insured limit">250,000</span> at certain times. There were <span id="xdx_906_eus-gaap--Cash_iI_do_c20231231_zRZmlm6mFZO4" title="Cash and cash equivalents"><span id="xdx_907_eus-gaap--Cash_iI_do_c20221231_zwFQKHojoMZc" title="Cash and cash equivalents">no</span></span> cash and cash equivalents which exceeded federally insured limits as of December 31, 2023 or 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No customer accounted for more than <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7wRKCdQWp2i" title="Concentration risk, percentage"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--NoCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWni5yfGsMtb" title="Concentration risk, percentage">10%</span></span> of sales or accounts receivable in each of the periods presented in the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Cash Cash	0	usd
CY2022Q4	us-gaap	Cash Cash	0	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84C_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zernaMITpNIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zJYbCGEbUN46">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1766	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	203043	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	203043	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-201277	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1766	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1196112	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	829844	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	423430	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1194209	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1619542	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2024053	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	21724	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	21724	usd
CY2023Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	12378	usd
CY2022Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	12378	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6828083	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6766208	usd
CY2023Q4	CANB	Medical Equipment MedicalEquipment	776396	usd
CY2022Q4	CANB	Medical Equipment MedicalEquipment	776396	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	26902	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	26902	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7665483	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7603608	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3559200	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2171251	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4106283	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5432357	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1387949	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1408061	usd
CY2023Q4	CANB	Finite Lived Technology Ip And Patents FiniteLivedTechnologyIpAndPatents	119998	usd
CY2022Q4	CANB	Finite Lived Technology Ip And Patents FiniteLivedTechnologyIpAndPatents	119998	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	119998	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	119998	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24854	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12854	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	95144	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	107144	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	12000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	12000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	12000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	12000	usd
CY2023Q4	CANB	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	35144	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	95144	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1354210	usd
CY2023Q4	CANB	Percentage Of Outstanding Common Stock PercentageOfOutstandingCommonStock	0.0999	pure
CY2022	CANB	Purchase Amount Of Future Receivables PurchaseAmountOfFutureReceivables	450000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	95000	usd
CY2023Q4	us-gaap	Share Price SharePrice	0.13
CY2022Q4	us-gaap	Share Price SharePrice	3.51
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0436	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0300	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.06	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.26	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	377654	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.11
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M19D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	679012	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.86
CY2022	CANB	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P4Y7D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1056666	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1056666	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.02
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.02
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y9M25D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	11166665	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.12
CY2023	CANB	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P4Y10M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12223331	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12223331	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.08
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.08
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M20D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M20D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1451665	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2371819	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	9596	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	793	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1647456	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3042141	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	9596	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	793	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	648286	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	942867	usd
CY2023	CANB	Income Tax Reconciliation Nondeductible Expense Share Based Interest IncomeTaxReconciliationNondeductibleExpenseShareBasedInterest	69076	usd
CY2022	CANB	Income Tax Reconciliation Nondeductible Expense Share Based Interest IncomeTaxReconciliationNondeductibleExpenseShareBasedInterest	15346	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	930094	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2083928	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9596	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	793	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	6685532	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5755437	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6685532	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5755437	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31836000	usd
CY2023	CANB	Operating Loss Carryforwards Expiration Date1 OperatingLossCarryforwardsExpirationDate1	that begin to expire in 2025.
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	294818	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	294818	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	40427	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	254391	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0892	pure

Files In Submission

Name	View Source	Status
0001493152-24-014686-index-headers.html	Edgar Link	pending
0001493152-24-014686-index.html	Edgar Link	pending
0001493152-24-014686.txt	Edgar Link	pending
0001493152-24-014686-xbrl.zip	Edgar Link	pending
canb-20231231.xsd	Edgar Link	pending
ex10-67.htm	Edgar Link	pending
ex10-68.htm	Edgar Link	pending
ex10-69.htm	Edgar Link	pending
ex10-70.htm	Edgar Link	pending
ex10-71.htm	Edgar Link	pending
ex10-72.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
canb-20231231_def.xml	Edgar Link	unprocessable
canb-20231231_lab.xml	Edgar Link	unprocessable
canb-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
canb-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CANB
Can B Corp Stock $canb

2024 Q2 Form 10-K Financial Statement

#000149315224014686 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CANB Can B Corp Stock $canb

2024 Q2 Form 10-K Financial Statement

#000149315224014686 Filed on April 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CANB
Can B Corp Stock $canb